EU/3/16/1805

About

On 12 December 2016, orphan designation (EU/3/16/1805) was granted by the European Commission to The Anticancer Fund, Belgium, for propranolol for the treatment of soft tissue sarcoma.

Key facts

Active substance
Propranolol
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
12/12/2016
Outcome
Positive
EU designation number
EU/3/16/1805

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

The Anticancer Fund
Boechoutlaan 221
1853-Strombeek-Bever
Belgium
Tel. +32 2 268 48 16
E-mail: info@anticancerfund.org

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating